Fas receptor

Autolus Therapeutics Announces Publication in Molecular Therapy Nucleic Acids

Retrieved on: 
Wednesday, April 26, 2023
Fas, TNF, CD95, Fas receptor, Survival, Research, Hematological Cancer Research Investment and Education Act, CAR, Apoptosis, Chimera, Neoplasm, Fas ligand, Vaccine

One such inhibitory factor is Fas ligand (FasL), which binds to the Fas receptor (CD95) on the surface of an activated T cell and triggers the CAR T cell to die by apoptosis.

Key Points: 
  • One such inhibitory factor is Fas ligand (FasL), which binds to the Fas receptor (CD95) on the surface of an activated T cell and triggers the CAR T cell to die by apoptosis.
  • The research group at Autolus tested several Fas chimeras which consist of the extracellular domain of Fas fused to the intracellular domain from different TNF receptor superfamily members.
  • Expression of these chimeras in a CAR T cell not only blocks apoptosis triggered by FasL, but results in co-stimulation, which promotes CAR T cell survival and proliferation.
  • These data support the potential of this Fas-CD40 chimera to render T cell therapies resistant to FasL-mediated cell death and improve their effectiveness against solid tumors.

ONL Therapeutics to Present at the XXVth Biennial Meeting of the International Society for Eye Research

Retrieved on: 
Monday, February 13, 2023
ONL, Fas receptor, European Association for Vision and Eye Research, Gold Coast Convention and Exhibition Centre, Safety, AMD, Patient, GA, International Society, Therapy, OAG, Convention center, ISER, ANN, Fas, Retina, Geographic atrophy, Pharmaceutical industry, Tobacco

ANN ARBOR, Mich., Feb. 13, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the company will deliver an oral presentation reviewing the scientific rationale for targeting the Fas receptor and the design of a Phase 1b study to evaluate the safety of ONL1204 ophthalmic solution for the treatment of patients with progressing open-angle glaucoma (OAG) at the upcoming XXVth Biennial Meeting of the International Society for Eye Research (ISER).

Key Points: 
  • ANN ARBOR, Mich., Feb. 13, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the company will deliver an oral presentation reviewing the scientific rationale for targeting the Fas receptor and the design of a Phase 1b study to evaluate the safety of ONL1204 ophthalmic solution for the treatment of patients with progressing open-angle glaucoma (OAG) at the upcoming XXVth Biennial Meeting of the International Society for Eye Research (ISER).
  • The ISER Meeting will take place February 19-23, 2023, at the Gold Coast Convention and Exhibition Centre in Broadbeach, Queensland, Australia.
  • Details of the presentation are as follows:
    1:00 p.m. Australian Eastern Standard Time on Tuesday, February 21, 2023
    As previously announced, ONL will also share new clinical data on ONL1204 Ophthalmic Solution in the treatment of patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD) in an oral presentation at the ISER Meeting.
  • Details of that presentation are as follows:

Chico's FAS, Inc. Announces First Quarter Sales and Earnings Conference Call

Retrieved on: 
Monday, May 17, 2021
Geography of California, Fas receptor, Immune system, Programmed cell death, Signal transduction, Chico, California, New York Stock Exchange, Sanibel, Florida, Sacramento Valley, California

b'FORT MYERS, Fla., May 17, 2021 /PRNewswire/ --Women\'s specialty retailer Chico\'s FAS, Inc. (NYSE: CHS) (the "Company") will host a conference call with security analysts on Tuesday, June 8, 2021 beginning at 8:00 a.m.

Key Points: 
  • b'FORT MYERS, Fla., May 17, 2021 /PRNewswire/ --Women\'s specialty retailer Chico\'s FAS, Inc. (NYSE: CHS) (the "Company") will host a conference call with security analysts on Tuesday, June 8, 2021 beginning at 8:00 a.m.
  • The Elite Entry number, 9636050, is required to join the conference call.
  • Interested participants should call 10-15 minutes prior to the 8:00 a.m. start to be placed in queue.\nChico\'s FAS is a Florida-based fashion company founded in 1983 on Sanibel Island, Fla.
  • The Company reinvented the fashion retail experience by creating fashion communities anchored by our Most Amazing Personal Service, which put the customer at the center of everything we do.